文献速递血栓与止血造血干细胞移植与细胞治疗

自体造血干细胞移植后血小板减少期间静脉血栓栓塞症的管理

Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation.
PubMed 文献 · Blood Adv · 2017-04-27

该观察性研究纳入2006至2015年间接受自体造血干细胞移植的淋巴瘤和骨髓瘤成人患者,分析移植前静脉血栓栓塞症(VTE)患者在血小板减少期间继续与暂停抗凝的结局。204例(12.5%)有移植前VTE事件,其中132例继续抗凝、72例暂停抗凝;两组30天内VTE复发(1.5% vs 1.4%)和大出血(3.8% vs 4.2%)无显著差异,继续抗凝组血小板输注次数显著更多。

要点

  • 自体移植前有VTE者占12.5%(204/1631),血小板减少期间132例继续抗凝、72例暂停抗凝。
  • 两组30天内VTE复发(1.5% vs 1.4%)与大出血(3.8% vs 4.2%)无显著差异。
  • 继续抗凝组血小板输注次数显著更高;血小板阈值或平均血小板计数均不能预测出血。

核心结论

  • 作者认为,对许多接受自体造血干细胞移植的患者,血小板减少期间暂停抗凝可能在现有选项中提供最佳的风险-获益权衡。

研究设计与样本

  • 观察性研究,纳入2006至2015年间接受自体造血干细胞移植的淋巴瘤和骨髓瘤成人患者。
  • 在1631例接受自体移植的患者中,204例(12.5%)有移植前指数VTE事件。
  • 按血小板减少开始时的抗血栓管理分为继续抗凝组132例和暂停抗凝组72例。

主要发现

  • 移植后30天内VTE复发:继续抗凝组1.5% vs 暂停抗凝组1.4%,无显著差异。
  • 移植后30天内大出血:继续抗凝组3.8% vs 暂停抗凝组4.2%,无显著差异。
  • 血小板输注次数在继续抗凝组显著更高。
  • 基线胆红素升高、肌酐升高和凝血酶原时间延长与大出血风险增加独立相关。
  • 血小板阈值和平均血小板计数均不能预测出血风险。

临床怎么用

  • 作者认为,对许多接受自体造血干细胞移植的患者,血小板减少期间暂停抗凝可能在现有选项中提供最佳的风险-获益权衡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Management of venous thromboembolism (VTE) remains challenging in patients with hematologic malignancy who undergo hematopoietic cell transplantation (HCT) due to prolonged thrombocytopenia. This study aims to (1) determine the incidence of VTE recurrence and bleeding during autologous HCT, (2) assess the impact of continuing vs temporarily withholding anticoagulation during thrombocytopenia, and (3) explore the impact of platelet threshold among other variables on the risk of bleeding. We performed this observational study in adults with lymphoma and myeloma who underwent autologous HCT between 2006 and 2015. We selected patients with index VTE prior to HCT and assigned them to different cohorts based on antithrombotic management at the onset of thrombocytopenia. Primary outcomes included VTE recurrence and major bleeding by 30 days after HCT. Secondary outcomes included platelet and red blood cell transfusions, time to engraftment, and overall survival. Of the 1631 patients who underwent autologous HCT, 204 patients (12.5%) had preceding index VTE events, and among them, 132 patients continued and 72 patients temporarily withheld anticoagulation during thrombocytopenia. There were no significant differences in VTE recurrence (1.5% vs 1.4%) or major bleeding (3.8% vs 4.2%) between 2 groups by 30 days. The number of platelet transfusions was significantly higher in the first group. Baseline elevated bilirubin, creatinine, and prothrombin time were independently associated with increased risk in major bleeding, whereas neither platelet threshold nor average platelet count was predictive. Our findings suggest that for many patients undergoing autologous HCT, temporarily withholding anticoagulation during thrombocytopenia may offer the best risk-benefit tradeoff among available options.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Li A, Davis C, Wu Q, et al. Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation. Blood Adv. 2017. PMID: 29296714. doi:10.1182/bloodadvances.2017006130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。